EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses

Over the last decade, therapies targeting immune checkpoints, such as programmed death-1 (PD-1), have revolutionized the field of cancer immunotherapy. However, low response rates and immune-related adverse events remain a major concern. Here, we report that epigallocatechin gallate (EGCG), the most...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravindran Menon, Dinoop, Li, Yang, Yamauchi, Takeshi, Osborne, Douglas Grant, Vaddi, Prasanna Kumar, Wempe, Michael F, Zhai, Zili, Fujita, Mayumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618268/
https://www.ncbi.nlm.nih.gov/pubmed/34832863
http://dx.doi.org/10.3390/ph14111081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618268/
https://www.ncbi.nlm.nih.gov/pubmed/34832863
http://dx.doi.org/10.3390/ph14111081

Ejemplares similares